Table 2.
Ongoing clinical trials using combined RT and ICI for treatment of advanced hepatocellular carcinoma.
| Trial Name | Start Date | Phase | Treatment | Patient Population | Primary End Point |
|---|---|---|---|---|---|
| NCT04167293 | 2019 | III | SRBT + Sintilimab vs SBRT alone | Advanced HCC with portal vein invasion | PFS at 24 weeks |
| NCT04913480 | 2020 | II | SBRT + Durvalumab | Advanced HCC | PFS at 1 year |
| NCT05488522 | 2022 | I | SBRT + Atezolizumab + Bevacizumab | Advanced HCC | Safety and efficacy |
| NCT04541173 | 2020 | II | Y90 TARE + Atezolizumab + Bevacizumab | Advanced HCC | PFS at 12 months |
| NCT05377034 | 2022 | II | SIRT-Y90 + Atzezolizumab + Bevacizumab | Locally Advanced HCC | Best Overall Response Rate at 12 months |
| NCT05701488 | 2023 | I | SIRT + Durvalumab + Tremelimumab | Resectable HCC | Adverse Events |
| NCT04169399 | 2019 | II | SBRT + Toripalimab | Advanced HCC with portal vein invasion | PFS at 6 months |
| NCT04988945 | 2020 | II | TACE + SBRT + durvalumab + tremelimumab | Advanced HCC | Downstaging to resection |
| NCT03857815 | 2019 | II | SBRT + Sintilimab | Advanced HCC | PFS at 2 years |
| ChiCTR 210049831 | 2022 | II | IMRT + atezolizumab + bevocizumab | Advanced HCC with portal vein tumor thrombosis | ORR |
| NCT05185531 | 2022 | I | Neoadjuvant SBRT + tislelizumab | Resectable HCC | Tumor response, safety and tolerability |
| NCT03316872 | 2018 | II | SBRT + Pembrolizumab | Advanced HCC | ORR |
HCC, Hepatocellular Carcinoma; ORR, Objective Response Rate; SBRT, Stereotactic Body Radiation Therapy; TACE, Trans arterial Chemoembolization; TARE, Trans arterialradioembolization; SIRT, Selective Internal Radiation Therapy; OS, Overall Survival; PFS, Progression Free Survival; IMRT, Intensity-modulated Radiotherapy.